Joseph Rafferty Net Worth

The estimated Net Worth of Joseph Rafferty is at least $3.14 mil dollars as of 24 November 2017. Joseph Rafferty owns over 7,000 units of Biosig Technologies Inc stock worth over $3,136 and over the last 7 years Joseph sold BSGM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Joseph Rafferty BSGM stock SEC Form 4 insiders trading

Joseph has made over 1 trades of the Biosig Technologies Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Joseph bought 7,000 units of BSGM stock worth $9,800 on 24 November 2017.

The largest trade Joseph's ever made was buying 7,000 units of Biosig Technologies Inc stock on 24 November 2017 worth over $9,800. On average, Joseph trades about 3,500 units every 0 days since 2017. As of 24 November 2017 Joseph still owns at least 7,000 units of Biosig Technologies Inc stock.

You can see the complete history of Joseph Rafferty stock trades at the bottom of the page.

What's Joseph Rafferty's mailing address?

Joseph's mailing address filed with the SEC is C/O BIOSIG TECHNOLOGIES, INC., 12424 WILSHIRE BLVD., SUITE 745, LOS ANGELES, CA, 90025.

Insiders trading at Biosig Technologies Inc

Over the last 9 years, insiders at Biosig Technologies Inc have traded over $1,778,587 worth of Biosig Technologies Inc stock and bought 1,345,515 units worth $2,296,289 . The most active insiders traders include Kenneth L Londoner, Asher Holzer, eJerome B Zeldis. On average, Biosig Technologies Inc executives and independent directors trade stock every 24 days with the average trade being worth of $11,433. The most recent stock trade was executed by Kenneth L Londoner on 13 June 2023, trading 15,600 units of BSGM stock currently worth $19,344.

What does Biosig Technologies Inc do?

biosig technologies, inc. (otcqb: bsgm) is a medical device company that is developing a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (ep) marketplace. led by a proven management team and a veteran, independent board of directors, minneapolis-based biosig is preparing to commercialize its pure ep system.

Complete history of Joseph Rafferty stock trades at Biosig Technologies Inc

Biosig Technologies Inc executives and stock owners

Biosig Technologies Inc executives and other stock owners filed with the SEC include:

• Kenneth Londoner,
  Executive Chairman of the Board, Chief Executive Officer
• Steven Chaussy,
  Chief Financial Officer
• Kenneth L. Londoner M.B.A., MBA,
  Founder, CEO & Exec. Chairman
• Samuel Navarro,
  Independent Director
• Jeffrey O'Donnell,
  Lead Independent Director
• Martha Pease,
  Independent Director
• Andrew Filler,
  Independent Director
• David Weild,
  Independent Director
• Patrick Gallagher,
  Independent Director
• Donald Foley,
  Independent Director
• Anthony Zook,
  Director
• Manasi Patwardhan,
  Director of Strategic Planning
• Olivier Chaudoir,
  Senior Director of Marketing
• Julie Stephenson,
  Vice President - Clinical Affairs, Senior Director of Clinical Affairs
• Andrew Ballou,
  Vice President - Investor Relations
• John Kowalski,
  Vice President - Sales
• John Sieckhaus,
  Chief Operating Officer
• Gray Fleming,
  Chief Commercial Officer
• Steven Chaussy,
  Chief Financial Officer
• Natasha Drapeau,
  Exec. VP
• Brenda Castrodad,
  Director of HR
• Lora Mikolaitis,
  VP of Admin.
• Dr. Budimir S. Drakulic Ph.D.,
  Chief Scientist
• Steven Eric Abelman,
  Director
• Steve Chaussy,
  Chief Financial Officer
• Roy T Tanaka,
  Director
• Lora Mikolaitis,
  10% owner
• Seth H. Z. Fischer,
  Director
• Joseph Rafferty,
  Chief Commercialization Offcr
• Jerome B Zeldis,
  Director
• Asher Holzer,
  Director
• Gregory D Cash,
  President and CEO
• James L Klein,
  Director
• James J Barry,
  Director
• John Sieckhaus,
  Chief Operating Officer
• Gray Fleming,
  Chief Commercial Officer
• Steven J Buhaly,
  Chief Financial Officer
• Frederick Hrkac,
  Director
• Donald Browne,
  Director
• Christopher Allen Baer,
  Director